Introduction Once initial treatment of multiple myeloma is complete, maintenance therapy, often involving lenalidomide or proteasome inhibitors, is the standard of care. However, maintenance therapy can cause a number of negative side effects, such as toxicity, thereby reducing quality of life. Minimal residual disease (MRD) is a key predictor of outcomes in [...]
Introduction In April 2024, the U.S. FDA’s Oncologic Drugs Advisory Committee (ODAC) unanimously (12–0) voted to accept minimal residual disease (MRD) negativity as a primary endpoint in multiple myeloma (MM) clinical trials seeking accelerated approval. This marks a regulatory shift, aiming to speed up the availability of new treatments. The decision stems [...]
Introduction Minimal residual disease (MRD) is a critical prognostic indicator in multiple myeloma, typically assessed using invasive bone marrow-based assays. However, these methods have shown limited success when applied to blood. Next-generation flow (NGF) is mainly useful in patients with high levels of circulating disease, which is a phenomenon that has been [...]
Introduction As detection technology and therapeutics have improved, minimal residual disease (MRD) has become a pivotal prognostic marker in multiple myeloma (MM), particularly for predicting progression free and overall survival. In 2024, the FDA consensus is that MRD negativity can be used as a clinical trial endpoint. This shift is driving innovation [...]
Introduction Here, we summarize a retrospective comparison of EasyM and Euroflow NGF for MRD in newly diagnosed multiple myeloma patients. Minimal residual disease (MRD) negativity is a critical measure of therapeutic response in multiple myeloma (MM) and is strongly associated with improved progression-free and overall survival. The IMWG (International Myeloma Working Group) [...]
Introduction Minimal residual disease (MRD) has emerged as a critical prognostic marker in multiple myeloma (MM). Traditional MRD assessment relies heavily on bone marrow–based methods such as multiparameter flow cytometry (MFC), next-generation flow cytometry (NGF), and next-generation sequencing (NGS). However, these are invasive, costly, and limited in their ability to capture disease [...]
Mariya Liyasova, Zac McDonald, Paul Taylor, Kathleen Gorospe, Xin Xu, Chenyu Yao, Qixin Liu, Liqiang Yang, Eshetu G Atenafu, Giovanni Piza, Bin Ma, Donna Reece, Suzanne Trudel DOI: 10.1158/1078-0432.CCR-21-0649 Publication Summary M-protein is a well-established biomarker used for multiple myeloma monitoring. Current improvements in multiple myeloma treatment created the need to monitor minimal residual disease (MRD) with high sensitivity. Measuring residual levels of [...]
Zac McDonald, Paul Taylor, Mariya Liyasova, Qixin Liu, Bin Ma DOI: 10.1021/acs.jproteome.0c01022 Publication Summary The amino acid sequence of the M-protein for multiple myeloma is unique compared to the polyclonal antibodies in patients’ blood. This uniqueness is exploited to develop an ultrasensitive M-protein detection method utilizing mass spectrometry (MS). This study demonstrates [...]